Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00340054
Other study ID # 99906013
Secondary ID 06-C-N0139999060
Status Completed
Phase N/A
First received June 19, 2006
Last updated March 7, 2012
Start date October 2005
Est. completion date March 2007

Study information

Verified date March 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

RATIONALE: Electric and magnetic fields may increase the risk of cancer. Developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure.

PURPOSE: This clinical trial is developing interview questions that can be used in estimating workplace exposure to electric and magnetic fields.


Description:

OBJECTIVES:

- Validate an interview-based electric and magnetic field exposure (EMF) assessment algorithm against measurements of the time-weighted average magnetic field magnitude used in previous epidemiologic studies.

- Calibrate the parameters in the algorithm in order to improve the exposure estimates.

- Correlate EMF exposure estimates from the algorithm with biologically based metrics measured by new instrumentation.

OUTLINE: Participants respond to questions during a 5- to 15-minute telephone interview concerning workplace exposure to electric and magnetic (EMF) fields. Data is collected during the interview using an exposure assessment algorithm designed to estimate EMF workplace exposure based on participants' responses. The interview-based estimates are then validated against actual field measurements of magnetic field exposure captured by Emdex multiwave monitors located at participating sites.


Other known NCT identifiers
  • NCT00481910

Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date March 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility DISEASE CHARACTERISTICS:

- Meets 1 of the following occupation criteria:

- Three occupations that primarily work in offices at Lawrence Livermore National Laboratories (LLNL)

- Three occupations that do nonelectric manual work (e.g., machinists and laborers) at LLNL

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Study Design

N/A


Related Conditions & MeSH terms


Intervention

Other:
questionnaire administration

Procedure:
study of high risk factors


Locations

Country Name City State
United States National Institute for Occupational Safety and Health Cincinnati Ohio
United States Exponent, Inc. Menlo Park California

Sponsors (2)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kelsh MA, Kheifets L, Smith R. The impact of work environment, utility, and sampling design on occupational magnetic field exposure summaries. AIHAJ. 2000 Mar-Apr;61(2):174-82. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of an interview-based electric and magnetic field (EMF) exposure assessment algorithm
Primary Calibration of algorithm parameters
Primary Correlation between EMF exposure estimates from the algorithm with biologically based metrics measured by new instrumentation
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00003464 - Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2